Jupiter Neurosciences shareholders clear reverse split and equity plan expansion as dilutive financing continues

summarizeSummary

Jupiter Neurosciences shareholders approved a reverse stock split and an expansion of the equity plan's share reserve. The company also revealed it has raised $4.1 million through its dilutive SEPA facility, issuing 12.5 million shares, with $1.5 million in convertible notes still outstanding.

check_boxKey Events · Corporate Governance and Compliance · JUNS

• Reverse Stock Split Approved

  A reverse stock split at a ratio between 1:10 and 1:100 was approved, with the board authorized to set the exact ratio and timing. The tally came in at 24.4 million votes for, 4.0 million against, and 49,132 abstentions.

• Equity Incentive Plan Expanded

  An amendment to the 2025 Equity Incentive Plan passed, adding 5.25 million shares to the reserve. The vote was 16.5 million for, 2.4 million against, and 142,751 abstentions.

• SEPA Financing Update

  Under the SEPA with Yorkville, the company has issued approximately 12.5 million shares for net proceeds of $4.1 million. About $1.5 million in convertible notes remain outstanding, convertible at $1.50 per share.

• Director Elections and Auditor Ratification

  All seven director nominees were elected, and Cherry Bekaert LLC was ratified as the independent auditor for fiscal year 2026.

auto_awesomeAnalysis · JUNS · Life Sciences

A reverse stock split at a ratio between 1:10 and 1:100, along with a 5.25 million share increase to the equity incentive plan, won shareholder approval. While the reverse split is essential to stave off a Nasdaq delisting, it does nothing to fix the underlying cash burn. The filing also discloses that the company has tapped its dilutive SEPA facility with Yorkville for $4.1 million in net proceeds, issuing 12.5 million shares, and still carries $1.5 million in convertible notes. Together, these governance moves and the ongoing dilution highlight a deeply precarious financial position.